Asset Dedication LLC’s ALX Oncology ALXO Stock Holding History

Asset Dedication LLC’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,463	Closed	-$11K	–	982
2023 Q2	$11K	Buy	+1,463	New	+$9.58K	﹤0.01%	651

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Asset Dedication LLC's ALXO Position: Q3 2023 in Review

Asset Dedication LLC sold out of ALX Oncology (ALXO) in Q3 2023, closing a stake of 1,463 shares — an estimated $11K sold.

Asset Dedication LLC first reported a position in ALXO in Q2 2023 and held it in 1 quarter. The position peaked at $11K in Q2 2023. 76 funds tracked by Wall St. Rank hold ALXO as of Q3 2023.

Asset Dedication LLC reported no remaining ALX Oncology position as of Q3 2023 after selling out during the quarter.
Asset Dedication LLC sold 1,463 ALX Oncology shares in Q3 2023, an estimated $11K.
Asset Dedication LLC first reported a position in ALX Oncology in Q2 2023 and held it in 1 quarter.
Asset Dedication LLC's ALX Oncology position peaked at $11K in Q2 2023.
76 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2023.

Based on Asset Dedication LLC's 13F filing for Q3 2023, filed 13 Nov 2023.